Clinical Trials Logo

Recurrent Osteosarcoma clinical trials

View clinical trials related to Recurrent Osteosarcoma.

Filter by:

NCT ID: NCT01190943 Completed - Clinical trials for Recurrent Osteosarcoma

DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma

Start date: August 6, 2010
Phase:
Study type: Observational

This research study is studying DNA biomarkers in tissue samples from patients with osteosarcoma. Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer. DNA analysis of tumor tissue may also help doctors predict how well patients will respond to treatment.

NCT ID: NCT01154816 Completed - Clinical trials for Recurrent Childhood Acute Lymphoblastic Leukemia

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Start date: February 2011
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the side effects of and how well alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia. Alisertib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01154452 Completed - Clinical trials for Gastrointestinal Stromal Tumor

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

Start date: June 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating patients with advanced or metastatic sarcoma. Vismodegib may slow the growth of tumor cells. Gamma-secretase/notch signalling pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vismodegib together with gamma-secretase/notch signalling pathway inhibitor RO4929097 may be an effective treatment for sarcoma.

NCT ID: NCT01016015 Completed - Clinical trials for Recurrent Osteosarcoma

Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma

Start date: November 2009
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well temsirolimus and cixutumumab works in treating patients with locally advanced, metastatic, or recurrent soft tissue sarcoma or bone sarcoma. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cixutumumab, can block tumor growth by blocking the ability of tumor cells to grow and spread. Giving temsirolimus with cixutumumab may be an effective treatment for soft tissue or bone sarcoma.

NCT ID: NCT00954473 Completed - Clinical trials for Recurrent Osteosarcoma

Study of Blood Samples From Patients With Osteosarcoma

Start date: January 2009
Phase: N/A
Study type: Observational

This research trial studies blood samples from patients with osteosarcoma. Studying the genes found in samples of blood from patients with osteosarcoma may help doctors identify biomarkers related to the disease.

NCT ID: NCT00831844 Completed - Clinical trials for Recurrent Neuroblastoma

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Start date: January 2009
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

NCT ID: NCT00331643 Completed - Clinical trials for Recurrent Neuroblastoma

Ixabepilone in Treating Young Patients With Refractory Solid Tumors

Start date: April 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well ixabepilone works in treating young patients with refractory solid tumors. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

NCT ID: NCT00330421 Completed - Clinical trials for Recurrent Osteosarcoma

Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)

Start date: June 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sorafenib works in treating patients with soft tissue sarcoma. Sorafenib may stop the growth of soft tissue sarcoma by blocking blood flow to the tumor and blocking some of the enzymes needed for tumor cell growth

NCT ID: NCT00101270 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

Start date: March 2005
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of oxaliplatin when given together with irinotecan in treating young patients with refractory solid tumors or lymphomas. Drugs used in chemotherapy, such as oxaliplatin and irinotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Oxaliplatin may help irinotecan kill more cancer cells by making cancer cells more sensitive to the drug. Giving oxaliplatin together with irinotecan may kill more cancer cells.

NCT ID: NCT00093821 Completed - Clinical trials for Recurrent Childhood Acute Lymphoblastic Leukemia

Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors

Start date: September 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of tanespimycin in treating young patients with recurrent or refractory leukemia or selected solid tumors. Drugs used in chemotherapy, such as tanespimycin, work in different ways to stop cancer cells from dividing so they stop growing or die.